Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial

202124 citationsJournal Articlehybrid Open Access

Authors

ClinicalTrials.gov, NCT02715284. Registration date: March 9, 2016.

Good health and well-being

Published in: Cancer Chemotherapy and Pharmacology

Volume 89, Issue 1, pp. 93-103

Field-Weighted Citation Impact: 1.70